Singapore vs Trinidad and Tobago: Treatment success rate for patients treated for MDR-TB
Singapore
39.0%
in 2022
Trinidad and Tobago
33.0%
in 2020
Singapore rank
150th
Trinidad and Tobago rank
151st
Treatment success rate for patients treated for MDR-TB over time
- Singapore
- Trinidad and Tobago
How they compare
Singapore currently reports 39.0% against 33.0% in Trinidad and Tobago, a difference of 6.0%.
That makes Singapore's figure about 1.2 times Trinidad and Tobago's.
The two have swapped places 1 time across 6 shared years of data; in 2013 it was Trinidad and Tobago ahead.
Singapore ranks 150th and Trinidad and Tobago ranks 151st of 163 countries.
Singapore has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Singapore | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 44.2% | 24.2% | 20.0% | Singapore |
| 2020s | 38.0% | 33.0% | 5.0% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Singapore or Trinidad and Tobago?
- Singapore, at 39.0% against 33.0% in Trinidad and Tobago as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Singapore and Trinidad and Tobago?
- 6.0%, with Singapore ahead.
- How many years of comparable data are there for Singapore and Trinidad and Tobago?
- 6 years are reported by both, from 2013 to 2020.
- How do Singapore and Trinidad and Tobago rank globally for treatment success rate for patients treated for mdr-tb?
- Singapore ranks 150th and Trinidad and Tobago ranks 151st of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.